Show simple item record

dc.contributor.authorJones, Robert J
dc.contributor.authorHawkins, Robert E
dc.contributor.authorEatock, Martin M
dc.contributor.authorFerry, David R
dc.contributor.authorEskens, Ferry A L M
dc.contributor.authorWilke, HansJochen
dc.contributor.authorEvans, T R Jeffry
dc.date.accessioned2009-03-17T17:10:36Z
dc.date.available2009-03-17T17:10:36Z
dc.date.issued2008-03
dc.identifier.citationA phase II open-label study of DHA-paclitaxel (Taxoprexin) by 2-h intravenous infusion in previously untreated patients with locally advanced or metastatic gastric or oesophageal adenocarcinoma. 2008, 61 (3):435-41 Cancer Chemother. Pharmacol.en
dc.identifier.issn0344-5704
dc.identifier.pmid17440725
dc.identifier.doi10.1007/s00280-007-0486-8
dc.identifier.urihttp://hdl.handle.net/10541/56022
dc.description.abstractPURPOSE: Combination chemotherapy regimens can improve survival in patients with advanced gastric and oesophageal adenocarcinoma. Docosahexaenoic acid (DHA)-paclitaxel is a novel conjugate formed by the covalent linkage of the fatty acid DHA to paclitaxel and may result in increased tumour exposure to paclitaxel without increased toxicity. PATIENTS AND METHODS: In this single arm, phase II study of DHA-paclitaxel, eligible patients with previously untreated, inoperable locally advanced or metastatic adenocarcinoma of the oesophagus, oesophago-gastric junction or stomach were treated with DHA-paclitaxel (1,100 mg/m(2)) administered by 2-h intravenous infusion every 21 days. RESULTS: Fifty-four patients were recruited of whom 53 were evaluable for toxicity, and 48 for response. There were five confirmed partial responses (9.4%) by the RECIST criteria. The median duration of response was 87 days (range 49-97 days), the median time to progression was 84 days (95% CI 78-124 days), and median overall survival was 262 days (95% CI 205-357 days). Grade >or=3 neutropaenia occurred in 93% of patients, and febrile neutropaenia in 17% of patients. CONCLUSIONS: DHA-paclitaxel has modest activity in patients with oesophago-gastric cancer and with haematological toxicity that is comparable to paclitaxel and docetaxel.
dc.language.isoenen
dc.subjectDHA-Paclitaxelen
dc.subjectOesopheal Canceren
dc.subjectStomach Canceren
dc.subjectCancer Metastasis
dc.subject.meshAdenocarcinoma
dc.subject.meshAdult
dc.subject.meshAged
dc.subject.meshAged, 80 and over
dc.subject.meshAntineoplastic Agents, Phytogenic
dc.subject.meshDisease Progression
dc.subject.meshDose-Response Relationship, Drug
dc.subject.meshEsophageal Neoplasms
dc.subject.meshFemale
dc.subject.meshHumans
dc.subject.meshInfusions, Intravenous
dc.subject.meshMale
dc.subject.meshMiddle Aged
dc.subject.meshNeoplasm Metastasis
dc.subject.meshPaclitaxel
dc.subject.meshStomach Neoplasms
dc.subject.meshSurvival Analysis
dc.subject.meshTomography, X-Ray Computed
dc.titleA phase II open-label study of DHA-paclitaxel (Taxoprexin) by 2-h intravenous infusion in previously untreated patients with locally advanced or metastatic gastric or oesophageal adenocarcinoma.en
dc.typeArticleen
dc.contributor.departmentCentre for Oncology and Applied Pharmacology, Beatson Oncology Centre, Western Infirmary, University of Glasgow, UK.en
dc.identifier.journalCancer Chemotherapy and Pharmacologyen
html.description.abstractPURPOSE: Combination chemotherapy regimens can improve survival in patients with advanced gastric and oesophageal adenocarcinoma. Docosahexaenoic acid (DHA)-paclitaxel is a novel conjugate formed by the covalent linkage of the fatty acid DHA to paclitaxel and may result in increased tumour exposure to paclitaxel without increased toxicity. PATIENTS AND METHODS: In this single arm, phase II study of DHA-paclitaxel, eligible patients with previously untreated, inoperable locally advanced or metastatic adenocarcinoma of the oesophagus, oesophago-gastric junction or stomach were treated with DHA-paclitaxel (1,100 mg/m(2)) administered by 2-h intravenous infusion every 21 days. RESULTS: Fifty-four patients were recruited of whom 53 were evaluable for toxicity, and 48 for response. There were five confirmed partial responses (9.4%) by the RECIST criteria. The median duration of response was 87 days (range 49-97 days), the median time to progression was 84 days (95% CI 78-124 days), and median overall survival was 262 days (95% CI 205-357 days). Grade >or=3 neutropaenia occurred in 93% of patients, and febrile neutropaenia in 17% of patients. CONCLUSIONS: DHA-paclitaxel has modest activity in patients with oesophago-gastric cancer and with haematological toxicity that is comparable to paclitaxel and docetaxel.


This item appears in the following Collection(s)

Show simple item record